Insilico Medicine and Servier announced a multi-year collaboration to accelerate the discovery of new cancer treatments by using artificial intelligence to tackle difficult oncology targets and shorten early-stage drug development timelines.
Insilico Medicine, the world's leading artificial intelligence (AI)-driven drug discovery company, announced a multi-year research and development (R&D) collaboration with Servier, an independent international pharmaceutical company. The partnership aims to use Insilico's proprietary AI platform, Pharma.AI, to identify and develop new treatments for difficult-to-drug targets in oncology.
The partnership aims to integrate advanced AI technology into early-stage drug discovery. This is a growing trend in the pharmaceutical industry, particularly in the cancer field, where unmet medical needs remain large.
Financial conditions and division of responsibility
Under the terms of the agreement, Insilico is eligible to receive up to US$32 million in upfront and short-term research and development costs. The company will lead the AI-driven discovery and development of potential drug candidates that meet pre-defined criteria. Meanwhile, Servier will share research and development costs and be responsible for clinical validation and commercialization of successful treatments.
Under the terms of the agreement, Insilico is eligible to receive up to US$32 million in upfront and short-term research and development costs.
The structure of this partnership combines Insilico's strengths in AI-powered discovery with Servier's global experience in clinical development and bringing medicines to market.
“This partnership underscores Servier's commitment to applying cutting-edge technology to address unmet medical needs for the benefit of patients and reflects our confidence in Insilico's in-house developed and validated AI platform,” said Christophe Thulieu, executive director of research at Servier.
Insilico Medicine (“Insilico”), the world’s leading artificial intelligence (AI)-driven drug discovery company, announced a multi-year research and development (R&D) collaboration with Servier, an independent international pharmaceutical company managed by the Foundation. This strategic partnership will leverage Insilico's proprietary AI platform, Pharma.AI, to focus on identifying and developing new treatments for difficult targets in oncology. Credit: Insilico Medicine
Trust in drug discovery using AI
For Insilico, the deal represents further validation of its approach to integrating generative AI across the pharmaceutical value chain. The company positions the Pharma.AI platform as a comprehensive system capable of target identification, molecule generation and optimization, and preclinical development.
For Insilico, the deal represents further validation of its approach to integrating generative AI across the pharmaceutical value chain.
Dr. Alex Zhavoronkov, Founder, CEO, and CBO of Insilico Medicine said: “As we deepen the integration of generative AI into every step of the pharmaceutical value chain, I believe the future of pharmaceutical superintelligence, where AI agents can actually make decisions and design experiments, driving a virtuous cycle of faster, smarter, and safer drug development, is never far away.”
Expanding the oncology pipeline and clinical advances
Insilico brings extensive oncology experience to the partnership. The company has built an extensive pipeline targeting multiple cancer indications, spanning both moderately novel and well-established biological mechanisms. Among its key assets are the potentially best-in-class pan-TEAD inhibitor ISM6331 and the MAT2A inhibitor ISM3412, both currently being evaluated in global, multicenter Phase I clinical trials.
Additionally, four other oncology programs are fully or partially licensed to partners and are in active Phase I trials.
Redefining timelines in preclinical development
Insilico reports that combining cutting-edge AI and automation technology has significantly increased the efficiency of preclinical drug development. Traditional early-stage drug discovery typically takes an average of 4.5 years. In contrast, Insilico nominated 20 preclinical candidates between 2021 and 2024, with an average timeline of only 12 to 18 months from project initiation to preclinical nomination.
Each program required just 60 to 200 molecules to synthesize and test, setting a new benchmark for AI-driven drug R&D and highlighting the potential impact of AI on accelerating innovation in oncology.
